TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
Brief Summary: Recent studies indicate that infusing 300 milliliters of water (in lieu of air) into the rectum and left colon through the colonoscope as it is being inserted during a colonoscopy examination can allow easier endoscope advancement. This method may prevent stretching of the colon, and ultimately reduce pain induced during colonoscopy. Improvements in patient comfort and cooperation, may increase the efficiency and success rate of complete colonoscopy. The purpose of the study is to test the efficacy of the water immersion technique in patients colonoscopy.


Options:
A: Intervention Type: PROCEDURE; Name: water infusion colonoscopy; Assigned to Arm(s): N/A
B: Arm Label: Air colonoscopy; Type: N/A; Interventions: N/A | Arm Label: Water colonoscopy; Type: N/A; Interventions: N/A
C: Arm Label: air insufflation; Type: PLACEBO_COMPARATOR; Interventions: Procedure: air insufflation | Arm Label: water immersion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: water immersion | Arm Label: water exchange; Type: ACTIVE_COMPARATOR; Interventions: Procedure: water exchange | Intervention Type: PROCEDURE; Name: air insufflation; Assigned to Arm(s): air insufflation | Intervention Type: PROCEDURE; Name: water immersion; Assigned to Arm(s): water immersion | Intervention Type: PROCEDURE; Name: water exchange; Assigned to Arm(s): water exchange
D: Arm Label: Water Immersion Colonoscopy; Type: EXPERIMENTAL; Interventions: Procedure: water immersion colonoscopy | Arm Label: Standard Air Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard air colonoscopy | Intervention Type: PROCEDURE; Name: water immersion colonoscopy; Assigned to Arm(s): Water Immersion Colonoscopy | Intervention Type: PROCEDURE; Name: standard air colonoscopy; Assigned to Arm(s): Standard Air Colonoscopy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT
Brief Summary: Two large homocysteine-lowering B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT. The main objective in these trials was to study the clinical effects of homocysteine-lowering therapy with folic acid and vitamin B12 in patients with established coronary artery disease. Follow-up was terminated for NORVIT on Marc 31st 2004 and for WENBIT October 5th 2005, and none of the two trials proved any protective effect of the B-vitamin intervention on cardiovascular outcomes.

There is so far no data on possible long-term effects following years of such B-vitamin treatment.

Thus, the main objective of the combinded NORVIT-WENBIT study will will be to evaluate the long-term effect of the B-vitamin intervention on incident life-style diseases including cardiovascular disease, diabetes, osteoporotic fractures and cancer.

A secondary object will be the identification of risk phenotypes or genotypes, and if such risk associations are midified by the B-vitamin intervention


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: N/A | Arm Label: 4; Type: N/A; Interventions: N/A
C: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
D: Arm Label: vitamin D3 and calcium carbonate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Calcium carbonate | Arm Label: Placebo for vitamin D3 and calcium carbonate; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Placebo for vitamin D3 and calcium carbonate, vitamin D3 and calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium carbonate; Assigned to Arm(s): Placebo for vitamin D3 and calcium carbonate, vitamin D3 and calcium carbonate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Arm Label: Bicalutamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Bicalutamide
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
C: Intervention Type: DRUG; Name: cyproterone acetate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: goserelin acetate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: orchiectomy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Brief Summary: The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine: 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine: 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 15 mg, Vortioxetine: 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine: 60 mg
B: Arm Label: Vortioxetine 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Duloxetine 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 2.5 mg, Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vortioxetine 10 mg or 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Agomelatine 25 mg or 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Agomelatine | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg or 20 mg | Intervention Type: DRUG; Name: Agomelatine; Assigned to Arm(s): Agomelatine 25 mg or 50 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Duloxetine 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 15 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Colon Cancer Screening Among African Americans
Brief Summary: RATIONALE: An interactive computer program may be more effective than a brochure in increasing colorectal cancer screening among African Americans.

PURPOSE: This randomized clinical trial is studying an interactive computer program to see how well it works compared with a brochure in increasing colorectal cancer screening among African Americans.


Options:
A: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: E-mail coaching to improve patient communication with doctor; Assigned to Arm(s): N/A
C: Arm Label: Non-tailored CRC screening brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-tailored CRC screening brochure | Arm Label: Interactive computer intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive computer intervention | Intervention Type: BEHAVIORAL; Name: Non-tailored CRC screening brochure; Assigned to Arm(s): Non-tailored CRC screening brochure | Intervention Type: BEHAVIORAL; Name: Interactive computer intervention; Assigned to Arm(s): Interactive computer intervention
D: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients
Brief Summary: This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit (SICU) patients. Subjects will be stratified by APACHE II score and randomized in 3:1 fashion to either biweekly surveillance using the β-D-glucan assay or standard care. Subjects in the active monitoring arm will receive intravenous anidulafungin should the β-D-glucan exceed 60 pg/mL on a single determination. Subjects in the standard care arm will have biweekly blood draws for β-D-glucan, but the specimens will be batched and tested retrospectively. Antifungal use in the standard care arm is at the discretion of the treating physicians. The primary study end-points are the feasibility of a preemptive antifungal strategy in a SICU setting, β-D-glucan test characteristics, and the safety and tolerability of preemptive anidulafungin. Risks associated with study participation include the risks associated with blood draws, study drug related side effects, and the potential for loss of confidentiality.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Arm Label: Antifungal; Type: ACTIVE_COMPARATOR; Interventions: Drug: anidulafungin | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: anidulafungin; Assigned to Arm(s): Antifungal
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empiric antifungal therapy based on physician discretion. | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Preemptive Therapy with Anidulafungin | Intervention Type: DRUG; Name: Preemptive Therapy with Anidulafungin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Empiric antifungal therapy based on physician discretion.; Assigned to Arm(s): 2
C: Arm Label: 1 prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caspofungin | Arm Label: 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Caspofungin; Assigned to Arm(s): 1 prophylaxis | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2 placebo
D: Arm Label: Nystatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nystatin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nystatin | Intervention Type: DRUG; Name: Nystatin; Assigned to Arm(s): Control, Nystatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: French Registry of Acute Coronary Syndrome With or Without ST Elevation
Brief Summary: The Fast-MI registry was designed to evaluate the "real world" management of patients with acute myocardial infarction (MI), and to assess their in-hospital, medium and long-term outcomes


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: Blood sample | Intervention Type: OTHER; Name: Blood sample; Assigned to Arm(s): 1
B: Arm Label: Early metoprolol initiation strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Injectable (i.v.) metoprolol tartrate (up to 15 mg). | Arm Label: Delayed metoprolol initiation strategy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Injectable (i.v.) metoprolol tartrate (up to 15 mg).; Assigned to Arm(s): Early metoprolol initiation strategy
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: Bicalutamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Bicalutamide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
B: Arm Label: Treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flutamide (Eulexin) and Lupron or Zoladex, Radiation: External Beam Radiotherapy | Arm Label: Treatment 2; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External Beam Radiotherapy | Intervention Type: DRUG; Name: Flutamide (Eulexin) and Lupron or Zoladex; Assigned to Arm(s): Treatment 1 | Intervention Type: RADIATION; Name: External Beam Radiotherapy; Assigned to Arm(s): Treatment 1, Treatment 2
C: Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: orchiectomy; Assigned to Arm(s): N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia
Brief Summary: The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive duloxetine at some point in the study.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Trazodone 20 mg | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Trazodone 10 mg | Arm Label: Group 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone 20 mg; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Trazodone 10 mg; Assigned to Arm(s): Group 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 3
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia
Brief Summary: The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive duloxetine at some point in the study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Milnacipran 100mg; Assigned to Arm(s): Milnacipran
B: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D